RUA — Rua Life Sciences Income Statement
0.000.00%
Last trade - 00:00
- £6.67m
- £6.62m
- £2.18m
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.463 | 0.489 | 1.53 | 1.63 | 2.18 |
Cost of Revenue | |||||
Gross Profit | — | — | 1.25 | 1.36 | 1.79 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.09 | 1.43 | 3.08 | 3.98 | 4.49 |
Operating Profit | -0.631 | -0.941 | -1.55 | -2.35 | -2.31 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -0.609 | -0.897 | -1.59 | -2.36 | -2.32 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.609 | -0.816 | -1.45 | -2.07 | -2 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.609 | -0.816 | -1.45 | -2.07 | -2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.609 | -0.816 | -1.45 | -2.07 | -2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.047 | -0.055 | -0.082 | -0.093 | -0.09 |